Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer

Investigators showed that secondary acquired HER2T862A and HER2L755S mutations promoted resistance to HER2 tyrosine kinase inhibitors via enhanced HER2 activation and impaired neratinib binding.